12:00 AM
Sep 24, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

BEMA Buprenorphine/Naloxone: Pivotal trial data

Top-line data from the crossover, pivotal BNX-103 trial in 63 healthy volunteers showed that BEMA Buprenorphine/Naloxone was comparable to sublingual Suboxone Buprenorphine/Naloxone in maximum plasma concentration (Cmax) and total exposure as measured by area under the curve (AUC). Additionally, BioDelivery said the naloxone component of the product was comparable to...

Read the full 239 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >